Stockscreener 앱 받기
13.31
4.04%
-0.56
시장 영업 전:
13.48
0.17
+1.28%
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying - Barchart.com
Intellia Therapeutics Announces Investor Conference Participation on May 5, 2026 - geneonline.com
Three Intellia fireside chats will stream live through June 3 - Stock Titan
Intellia Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi - The National Law Review
ARK Invest Increases Stake in Intellia Therapeutics (NTLA) Amid Sector Rotation - GuruFocus
Intellia Therapeutics says its CRISPR-based treatment succeeds in pivotal trial - MSN
Lonvo-z gene-editing therapy lowers HAE attacks by 87% in Phase 3 trial - Angioedema News
Intellia Initiates Rolling BLA Submission For In Vivo CRISPR Therapy In Hereditary Angioedema - marketscreener.com
NTLA stock rises 20% in 3 months: Here's what you should know - MSN
Behavioral Patterns of NTLA and Institutional Flows - Stock Traders Daily
Intellia Therapeutics shares slip despite strong phase 3 data - MSN
symbol__ Stock Quote Price and Forecast - CNN
NTLA jumps premarket on positive late-stage trial data for gene-editing therapy — retail says buy now before it’s too late - MSN
Intellia Therapeutics, Inc. Sued for Securities Law Violations - GuruFocus
Intellia Therapeutics (NTLA) Sees Major Purchase by ARK Investme - GuruFocus
Cathie Wood’s ARK sells AMD stock, buys Roblox and Intellia - Investing.com
Intellia Therapeutics Prices Public Equity Offering to Fund Pipeline - The Globe and Mail
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
43 new Intellia employees get stock awards worth 208,850 shares - Stock Titan
Intellia Therapeutics prices $180M stock offering at discount - MSN
Intellia Therapeutics | DEF 14A: Definitive information statements - Moomoo
Intellia Therapeutics (NTLA) Is Down 15.1% After Phase 3 lonvo-z Data And $180M Equity RaiseHas The Bull Case Changed? - Yahoo Finance
Intellia Therapeutics | SCHEDULE 13G: Others - Moomoo
Intellia (NASDAQ: NTLA) equity sale boosts cash runway into 2028 - Stock Titan
Intellia Therapeutics (NASDAQ: NTLA) sets 2026 virtual meeting on directors, pay and auditor - Stock Titan
MSN Money - MSN
NTLA Stock Draws Bulls After Phase 3 Gene-Editing Win - StocksToTrade
[ARS] Intellia Therapeutics, Inc. SEC Filing - Stock Titan
Vanguard (NTLA) files Schedule 13G reporting 5.03% ownership (5.95M) - Stock Titan
Intellia Therapeutics | 424B5: Prospectus - Moomoo
NTLA Forecast, Price Target & Analyst Ratings | INTELLIA THERAPEUTICS INC (NASDAQ:NTLA) - ChartMill
ARK Investment Acquires 2.4 Million Shares of Intellia Therapeutics (NTLA) - GuruFocus
$Intellia Therapeutics (NTLA.US)$ Hope u will give me good profit starr from today - Moomoo
Intellia Therapeutics (NASDAQ: NTLA) offers 16.7M shares at $10.75 - Stock Titan
NTLA Stock Slides As $150M Offering Signals Dilution Risk - timothysykes.com
Vanguard Portfolio Management holds 5.3% of Intellia (NASDAQ: NTLA) - Stock Titan
Intellia Therapeutics earnings in focus after gene editing breakthrough By Investing.com - Investing.com South Africa
Intellia Therapeutics earnings in focus after gene editing breakthrough - Investing.com UK
NTLA Stock Pressured As $150M Offering Tests Trader Nerves - StocksToTrade
NTLA Secures $180 Million in Increased Common Stock Offering - GuruFocus
Intellia Therapeutics (NTLA) Launches $180M Public Offering Amid Share Price Drop - GuruFocus
Intellia Therapeutics stock tumbles on discounted offering - Investing.com
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Intellia Therapeutics (NTLA) and Incyte (INCY) - The Globe and Mail
NTLA Stock Slips As $150M Equity Offering Raises Dilution Fears - timothysykes.com
Intellia Files BLA After Lonvo-z Meets Phase 3 Endpoints - CRISPR Medicine News
Intellia Therapeutics stock tumbles on discounted offering By Investing.com - Investing.com India
Intellia Therapeutics stock tumbles on dilutive offering By Investing.com - Investing.com Canada
Intellia Therapeutics stock tumbles on dilutive offering - Investing.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA), Biogen (BIIB) and HCA Healthcare (HCA) - The Globe and Mail
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock - The Manila Times
0.14%
0.48%
자본화:
|
볼륨(24시간):